Conclusions
The present study shows that RDV remained an effective treatment of COVID-19 during Delta and Omicron SARS-CoV-2 waves. Under the dominance of both viral lineages, the mortality of hospitalized patients treated with RDV was significantly lower than in those who did not receive any antiviral treatment, despite the fact that these groups did not differ in demographic and clinical characteristics. Despite the milder course of infections caused by the Omicron variant, RDV continues to be an important element of COVID-19 therapy.